Source - SMW
Tristel has received regulatory approval for its Fuse for Surfaces and Jet for Surfaces disinfectant products from the Therapeutic Goods Association (TGA), the body that regulates disinfectant use in Australia.  

Both Tristel products have been approved as Hospital Grade Disinfectants and will be permitted to make efficacy claims against bacterial spores including Clostridium difficile.

The Australian hospital market constitutes 750 public hospitals and 290 private hospitals, and the problems associated with hospital-acquired infections in Australia are very similar to the UK.

In the UK, Fuse and Jet for Surfaces generated sales of approximately £1.2 million in the 2016 financial year.

Tristel has had a presence in the Australian hospital market since 2011 when it received its first approval from the TGA for its Wipes System for the disinfection of small medical instruments.  From 2011 to July 2016 Tristel sold its Wipes System via a distributor. 

During the year ended 30 June 2016 the distributor's sales of the Wipes System were approximately AU$3 million (c. £1.7 million). On 18 July Tristel purchased the distributor's business and established a direct presence in the Australian healthcare market via its wholly-owned subsidiary, Tristel Pty Limited.

Related Charts

Tristel (TSTL)

+2.50p (+1.74%)
delayed 14:53PM